Memorial Sloan-Kettering Cancer Center (MSKCC) Risk of Recurrence
Predicts the 5-year probability of treatment failure among patients with newly diagnosed renal cell carcinoma (RCC).
Advice
Use results alongside a thorough clinical evaluation, clinician judgment, local guidelines, and specialist input to guide:
- Prognosis counseling.
- Follow-up intensity, including visit frequency, laboratory studies, and imaging.
- Adjuvant therapy decisions, such as whether to use pembrolizumab.
- Clinical trial enrollment.